Read/Write Labs Debuts to Build AI Platform That Writes Code for the Brain

Read/Write Labs, formerly known as Dandelion Science, has launched as a research and technology company aiming to build an industry-first AI platform capable of writing code for the brain. The organization announced an expanded executive and advisory team, including computational neuroscience and artificial intelligence figures such as Jim DiCarlo, Dan Yamins, and Stephen Wolfram. The company's stated mission involves developing precision therapies for brain disorders, improving cognitive function, and leveraging biological intelligence insights to inform human-centered artificial intelligence systems.

Leadership and Scientific Team

The company operates under the leadership of co-founders Adam Hanina, serving as CEO, and Chief Scientific Officer Martin Schrimpf, who is the creator of Brain-Score and leader of the NeuroAI Lab at EPFL. The newly expanded advisory and executive roster includes:

• Professor James DiCarlo: External Scientific Fellow and MIT professor focusing on visual information representation and machine-executable scientific models.
• Professor Dan Yamins: External Scientific Fellow and Stanford University professor specializing in artificial intelligence models of the brain.
• Stephen Wolfram: External Advisor, founder and CEO of Wolfram Research, and creator of Mathematica and Wolfram|Alpha.
• Katherine Fairchild: Chief Technology Officer, formerly Senior Director of AI/ML at Digital Diagnostics and engineering leader at the MIT Siegel Family Quest for Intelligence.
• Ben Lönnqvist: Head of NeuroAI, holding a PhD in Computational Neuroscience from EPFL.

Core Technologies and Objectives

Read/Write Labs focuses on bridging biological and machine intelligence through a dual approach. According to the company's announcements, the platform aims to:

• Digital Brains: Develop AI models designed to predict how real brains respond to sensory or direct neural stimulation, potentially allowing for in silico treatment design and testing.
• Precision Therapies: Write precise patterns of activity to treat neurological disorders and improve cognition.
• AI Alignment: Explore whether human brain data can assist in developing artificial intelligence systems that are safer and more aligned with human values.

Verification and Funding Status

Official corporate announcements indicate that Read/Write Labs holds a patent portfolio comprising over 30 pending and granted patents. The organization has received funding support from entities including the National Institutes of Health, the Swiss Government, and the Wyss Center for Bio and Neuroengineering. Independent observers and prospective partners can verify official updates and disclosures directly through the company's public channels and official press releases.